---
id: sgkb.data.biomedical-pharma-anchors
kind: dataset
title: "Biomedical and Pharma Anchors"
url: https://ik.sg/en/knowledge/dataset/sgkb.data.biomedical-pharma-anchors
language: en
evidence_status: verified
last_verified: 2026-08-09
collection_as_of: 2026-11-22
---

# Biomedical and Pharma Anchors

Dated Singapore biomedical manufacturing scale, GDP contribution, plant counts, and Biopolis/Tuas anchors — distinct from clinical healthcare financing.

# Biomedical and Pharma Anchors

Use each row with its as-of date. Manufacturing regulation (HSA) is distinct from clinical healthcare (MOH). Narrative lives in [biomedical and pharma](/en/knowledge/article/sgkb.business-industry.biomedical-and-pharma).

## Scale and GDP contribution

| Metric | Value | Denominator / notes | As of |
|---|---|---|---|
| BMS GDP contribution | About 1.9% of GDP | Biopharmaceutical + medical technology activity | 2024 |
| Product value for global markets | More than S$32 billion | >85% increase vs two decades earlier | 2024 framing |
| Manufacturing plants | More than 60 | BMS manufacturing plants in Singapore | Accessed Aug 2026 |
| R&D centres | More than 30 | Corporate/public research centres | Accessed Aug 2026 |
| Regional headquarters | More than 80 | Including eight of top 10 biopharma firms (gov framing) | Accessed Aug 2026 |

Source: [EDB biomedical powerhouse](https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html), accessed 9 August 2026.

## Manufacturing cluster share (April 2026)

| Metric | Value | Notes | As of |
|---|---:|---|---|
| Biomedical share of manufacturing output | 11.3% | Index basis 2025=100 | Apr 2026 |
| Pharmaceuticals share | 3.7% | Within manufacturing output index | Apr 2026 |
| Medical technology share | 7.6% | Within manufacturing output index | Apr 2026 |
| Biomedical output YoY | −16.1% | Softer devices + lower biologics | Apr 2026 |

Source: [EDB Monthly Manufacturing Performance](https://www.edb.gov.sg/en/about-edb/media-releases-publications/monthly-manufacturing-performance.html), with the [April 2026 media release](https://www.edb.gov.sg/content/dam/edb-en/about-edb/media-releases/manufacturing-statistics/Monthly_Manufacturing_Activities/Monthly%20Manufacturing%20Performance%20April%202026.pdf), accessed 14 August 2026.

## Investment and campuses

| Anchor | Value | Notes | As of |
|---|---|---|---|
| Fixed-asset investments (BMS) | S$4.4 billion | Projected 1,775 jobs over five years | 2025 |
| Biopolis | Opened Oct 2003 | one-north biomedical R&D campus | 2003 |
| Tuas Biomedical Park | Manufacturing park (JTC) | Distinct from clinical hospitals | Ongoing |

Source: [MTI PQ reply](https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/); EDB/NAS campus framing, accessed 9 August 2026.

## Record details

- **Also known as:** BMS manufacturing; Tuas Biomedical Park; Biopolis
- **Source format:** markdown
- **Classification confidence:** high
- **Classification source:** curated
- **All domains:** data
- **Entities:** [Singapore Economic Development Board](https://ik.sg/en/knowledge/entity/sg.agency.edb); [Agency for Science, Technology and Research](https://ik.sg/en/knowledge/entity/sg.agency.astar); [Health Sciences Authority](https://ik.sg/en/knowledge/entity/sg.agency.hsa)
- **Facets:** business; current; institution; policy; statistics
- **Geographic scope:** national
- **What each row represents:** one dated BMS GDP/plant/VA or campus investment anchor
- **Jurisdiction:** SG
- **Language:** en
- **Last verified:** 2026-08-09
- **Explore connections:** biomedical-and-pharma; astar-and-public-research; doing-business
- **Status:** verified
- **Tags:** manufacturing; statistics; policy; investment
- **Temporal scope:** current
- **All topics:** [Biomedical and pharmaceuticals](https://ik.sg/en/knowledge/topic/sgtopic.business.biomedical-pharma)
- **Update cadence:** after EDB manufacturing stats or BMS investment announcements
- **Volatility:** fast

## Sources

- [EDB — Singapore's rise as a biomedical sciences powerhouse](https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html) — Accessed 2026-08-09
- [EDB — Monthly Manufacturing Performance](https://www.edb.gov.sg/en/about-edb/media-releases-publications/monthly-manufacturing-performance.html) — Accessed 2026-08-09
- [EDB — Monthly Manufacturing Performance April 2026 infographic](https://www.edb.gov.sg/content/dam/edb-en/about-edb/media-releases/manufacturing-statistics/Monthly_Manufacturing_Activities/Monthly%20Manufacturing%20Performance%20April%202026.pdf) — Accessed 2026-08-14
- [MTI — Written reply on biomedical sector resilience](https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/) — Accessed 2026-08-09

## Explore connections

- Articles: [A*STAR and Public Research Institutes](https://ik.sg/en/knowledge/article/sgkb.science-research.astar-and-public-research)
- Articles: [Biomedical and Pharma](https://ik.sg/en/knowledge/article/sgkb.business-industry.biomedical-and-pharma)
- Articles: [Doing Business in Singapore](https://ik.sg/en/knowledge/article/sgkb.business-industry.doing-business)
- Topics: [Biomedical and pharmaceuticals](https://ik.sg/en/knowledge/topic/sgtopic.business.biomedical-pharma)
- People & organisations: [Agency for Science, Technology and Research](https://ik.sg/en/knowledge/entity/sg.agency.astar)
- People & organisations: [Health Sciences Authority](https://ik.sg/en/knowledge/entity/sg.agency.hsa)
- People & organisations: [Singapore Economic Development Board](https://ik.sg/en/knowledge/entity/sg.agency.edb)

Dates describe this record’s own period and applicability. A verification date does not mean a rule is currently in force. An expanding collection. Published counts show available knowledge, not complete coverage of Singapore.
